FDA
-
-
-
-
-
-
-
Moderna Advances Multiple Vaccine Programs to Late-Stage Clinical Trials
-
-
-
-
-
-
-
'Unlikely' Moderna can file for accelerated approval says analyst; Shares jump 12%
-
-
-
-
-
-
-
Moderna (MRNA) Reports Positive Clinical Results Across Cancer, Rare Disease, and Infectious Disease
-
-
-
-
-
-
-
Moderna (MRNA) said updated Covid-19 vaccine effective against BA.2.86 (Pirola) variant
-
-
-
-
-
-
-
Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma
-
-
-
-
-
-
-
Moderna (MRNA) and Merck (MRK) Announce mRNA-4157 in Combination With KEYTRUDA Demonstrated a Statistically Significant and Clinically Meaningful Improvement in Distant Metastasis-Free Survival in Pat
-
-
-
-
-
-
-
Moderna (MRNA) Announces Clinical and Program Updates at 4th Vaccines Day
-
251,412 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All